Benzinga··PrnewswireVolitionRx Triples Q1 Revenue Amid Surge in Clinical Breakthroughs and Licensing Talks
VolitionRx reported 300% Q1 revenue growth to $1M, submitting cancer detection manuscript and advancing multiple diagnostic platforms toward commercialization.
VNRXcancer detectionliquid biopsy